Micralyne, a manufacturer of biomedical MEMS and sensors, announced this week the launch MicraFluidics, a set of standardized microfluidic process technologies, to support demand from the biomedical and life-sciences industry for rapid design and deployment of integrated microfluidic based products. MicraFluidics features a variety of substrate options for biomedical customers such as silicon, glass, and silicon-on-insulator (SOI) with design flexibility for multi-level channels, electrode patterning for dielectrophoresis and embedded sensors, and choices of glass or silicon as input and output ports. This technology has been validated in a wide range of devices such as flow cells, biochips, labs-on-chip, cell sorters, separation and analysis devices, and high-pressure analytical chips.
"Micralyne has been on the forefront of microfluidic development, having first developed glass micromachining technology in the 1990s. Early devices were cavities in glass for cell manipulation, and quickly evolved to bonded channel devices. We have advanced the technology considerably over the last three decades, and are excited to offer these innovations as standard microfluidic processes," said Glen Fitzpatrick, the company's Chief Scientific Officer. "It can be challenging to find foundries that manufacture microfluidic devices and meet the stringent quality compliance requirements of the biomedical industry. Micralyne is one of a handful of MEMS foundries with ISO 13485 certification," Mr. Fitzpatrick added.
Micralyne's MEMS process technology platforms provide a modular approach to MEMS design and enable fast prototyping with semi-custom device implementations, and rapid manufacturing ramp-up without sacrificing product quality and consistency. Micralyne started providing standard processes and MEMS building blocks in 2006 with an effort to lower MEMS development costs and accelerate MEMS time-to-market for customers.
"Over the last two years we have seen a dramatic increase in demand from our customers for microfluidic biochips for a wide range of end applications, such as point-of-care diagnostics, treatment planning, drug delivery, and oncology research," said Paul Pickering, Micralyne's Chief Revenue officer. "We understand that time-to-market is critical for our biomedical customers, and therefore have developed the MicraFluidics technology to enable our customers to rapidly convert their ideas to manufacturable products," Mr. Pickering added.
Micralyne is exhibiting this technology and other offerings at MD&M West, one of the largest medtech conference in North America on February 6-8, 2018 at the Anaheim Convention Center.
Micralyne is one of the world's leading independent developers and manufacturers of MEMS and micro-fabricated products. Headquartered in Edmonton, Alberta, Canada, Micralyne's customer base includes Fortune 500 companies, mid-range industrial and biomedical companies, and pioneering high-tech startups.
This article is a part of MEMS Journal's ongoing market research project in the area of MEMS and NEMS manufacturing. If you would like to receive our comprehensive market research report on this topic, please contact Dr. Mike Pinelis at firstname.lastname@example.org for more information about rates and report contents.
Copyright 2018 MEMS Journal, Inc.